277 related articles for article (PubMed ID: 32791395)
1. Hypoxia-mediated cancer stem cell resistance and targeted therapy.
Sun X; Lv X; Yan Y; Zhao Y; Ma R; He M; Wei M
Biomed Pharmacother; 2020 Oct; 130():110623. PubMed ID: 32791395
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells.
Hajizadeh F; Okoye I; Esmaily M; Ghasemi Chaleshtari M; Masjedi A; Azizi G; Irandoust M; Ghalamfarsa G; Jadidi-Niaragh F
Life Sci; 2019 Nov; 237():116952. PubMed ID: 31622608
[TBL] [Abstract][Full Text] [Related]
3. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
Nozawa-Suzuki N; Nagasawa H; Ohnishi K; Morishige K
Biochem Biophys Res Commun; 2015 Feb; 457(4):706-11. PubMed ID: 25619133
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cell (CSC) resistance drivers.
Najafi M; Mortezaee K; Majidpoor J
Life Sci; 2019 Oct; 234():116781. PubMed ID: 31430455
[TBL] [Abstract][Full Text] [Related]
5. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
[TBL] [Abstract][Full Text] [Related]
6. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.
Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT
Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674
[TBL] [Abstract][Full Text] [Related]
7. Cancer Stem Cells and Targeting Strategies.
Barbato L; Bocchetti M; Di Biase A; Regad T
Cells; 2019 Aug; 8(8):. PubMed ID: 31426611
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
Rohwer N; Cramer T
Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors HIF1α and HIF2α.
Schöning JP; Monteiro M; Gu W
Clin Exp Pharmacol Physiol; 2017 Feb; 44(2):153-161. PubMed ID: 27809360
[TBL] [Abstract][Full Text] [Related]
10. MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer.
Roscigno G; Puoti I; Giordano I; Donnarumma E; Russo V; Affinito A; Adamo A; Quintavalle C; Todaro M; Vivanco MD; Condorelli G
Oncotarget; 2017 Mar; 8(12):19507-19521. PubMed ID: 28061479
[TBL] [Abstract][Full Text] [Related]
11. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
12. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.
Conley SJ; Baker TL; Burnett JP; Theisen RL; Lazarus D; Peters CG; Clouthier SG; Eliasof S; Wicha MS
Breast Cancer Res Treat; 2015 Apr; 150(3):559-67. PubMed ID: 25833208
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma.
Kumar D; Gorain M; Kundu G; Kundu GC
Mol Cancer; 2017 Jan; 16(1):7. PubMed ID: 28137308
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors.
Semenza GL
Clin Sci (Lond); 2015 Dec; 129(12):1037-45. PubMed ID: 26405042
[TBL] [Abstract][Full Text] [Related]
15. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
[TBL] [Abstract][Full Text] [Related]
16. Targeting hypoxia for sensitization of tumors to radio- and chemotherapy.
Ghattass K; Assah R; El-Sabban M; Gali-Muhtasib H
Curr Cancer Drug Targets; 2013 Jul; 13(6):670-85. PubMed ID: 23687923
[TBL] [Abstract][Full Text] [Related]
17. The bad seed: Cancer stem cells in tumor development and resistance.
Koren E; Fuchs Y
Drug Resist Updat; 2016 Sep; 28():1-12. PubMed ID: 27620951
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cells (CSCs) in cancer progression and therapy.
Najafi M; Farhood B; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8381-8395. PubMed ID: 30417375
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance.
Najafi M; Farhood B; Mortezaee K; Kharazinejad E; Majidpoor J; Ahadi R
J Cancer Res Clin Oncol; 2020 Jan; 146(1):19-31. PubMed ID: 31734836
[TBL] [Abstract][Full Text] [Related]
20. Role of hypoxia-inducible factors (HIF) in the maintenance of stemness and malignancy of colorectal cancer.
Vadde R; Vemula S; Jinka R; Merchant N; Bramhachari PV; Nagaraju GP
Crit Rev Oncol Hematol; 2017 May; 113():22-27. PubMed ID: 28427511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
